Unleashing the Power of Tregs

Clinical Trials for Neurodegenerative Diseases

Multiple Treg therapeutic modalities addressing neurodegenerative, autoimmune, and metabolic disease

View Available Trials

Unleashing the Power of Tregs

Multiple Treg therapeutic modalities addressing neurodegenerative, autoimmune, and metabolic disease

View Available Trials

Unleashing the Power of Tregs

Clinical Trials for Neurodegenerative Diseases

Multiple Treg therapeutic modalities addressing neurodegenerative, autoimmune, and metabolic disease

View Available Trials

About Coya Therapeutics

Coya Therapeutics is a clinical-stage biotechnology company focused on developing proprietary therapies to enhance the function of regulatory T cells (Tregs). Our multi-modality pipeline includes Treg-enhancing biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy, targeting conditions where dysfunctional Tregs contribute to disease progression.

Our Clinical Programs

Explore our current clinical trial opportunities

COYA 302

Amyotrophic Lateral Sclerosis (ALS)

Fully Enrolled

ALSTARS Trial: Study of COYA 302 for the Treatment of ALS

A Phase 2 clinical trial evaluating COYA 302, an investigational Treg-enhancing combination therapy, for adults with ALS.

Phase 2
25 Sites
Learn More

COYA 302

Frontotemporal Dementia (FTD)

Coming Soon

COYA 302 for Frontotemporal Dementia (FTD)

An upcoming clinical trial evaluating COYA 302 for the treatment of Frontotemporal Dementia.

Phase 2 (Planned)
10 Sites
Check Back for Updates
Expanded Access Policy

COYA 302 for ALS

Treg Enhancing Biologics

Combination therapy currently enrolling patients with Amyotrophic Lateral Sclerosis (ALS)

  • Currently Enrolling

COYA 302 for FTD

Treg Enhancing Biologics

Combination therapy for Frontotemporal Dementia - FDA IND accepted January 2026

  • Coming Soon